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Abstract: Alcohol consumption in young women is a widespread habit that may continue during
pregnancy and induce alterations in the fetus. We aimed to characterize prevalence of alcohol
consumption in parturient women and to assess fetal ethanol exposure in their newborns by analyzing
two direct metabolites of ethanol in meconium. This is a cross-sectional study performed in September
2011 and March 2012 in a series of women admitted to an obstetric unit following childbirth. During
admission, socio-demographic and substance use (alcohol, tobacco, cannabis, cocaine, and opiates)
during pregnancy were assessed using a structured questionnaire and clinical charts. We also recorded
the characteristics of pregnancy, childbirth, and neonates. The meconium analysis was performed
by liquid chromatography—tandem mass spectrometry (LC-MS/MS) to detect the presence of
ethyl glucuronide (EtG) and ethyl sulfate (EtS). Fifty-one parturient and 52 neonates were included
and 48 meconium samples were suitable for EtG and EtS detection. The median age of women
was 30 years (interquartile range (IQR): 26–34 years); EtG was present in all meconium samples
and median concentration of EtG was 67.9 ng/g (IQR: 36.0–110.6 ng/g). With respect to EtS, it was
undetectable (<0.01 ng/g) in the majority of samples (79.1%). Only three (6%) women reported alcohol
consumption during pregnancy in face-to-face interviews. However, prevalence of fetal exposure to
alcohol through the detection of EtG and EtS was 4.2% and 16.7%, respectively. Prevention of alcohol
consumption during pregnancy and the detection of substance use with markers of fetal exposure are
essential components of maternal and child health.
Keywords: fetal ethanol exposure; meconium; ethyl glucuronide; ethyl sulfate
1. Introduction
Alcohol consumption is socially accepted in Western countries and the consequences of hazardous
drinking are often minimized. In women of childbearing age, it may represent a serious health problem
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because of the risk of congenital malformations and neurodevelopmental alterations in newborns [1,2].
The extreme clinical effects of fetal exposure to alcohol were described decades ago [3]. Since then,
the Fetal Alcohol Syndrome (FAS) has become a well-recognized clinical picture that is associated
with high medical consequences and social costs. In the United States, FAS is considered the primary
cause of preventable birth defects [4,5] and the most serious consequence of drinking alcohol during
pregnancy, with the exception of intrauterine fetal death. Clinically, FAS is characterized by low birth
weight, a distinctive phenotype with central nervous system alterations and behavioral deficiencies
during development. The incidence of FAS is 0.5–1.5 per 1000 births per year [6], although the range of
clinical effects induced by alcohol consumption during pregnancy is much greater and includes Fetal
Alcohol Spectrum Disorder (FASD). The incidence of FASD is approximately 1% of live births [6,7].
In recent years, it has become clear that adolescent and young women from Western countries
are drinking alcohol at a similar rate to men. In Spain, approximately 70% of young women have
consumed alcohol in the last year, and 50% have consumed alcohol in the last month [8].
According to a study in the US, 60% of women of childbearing age consume alcohol occasionally,
and 13% exhibit hazardous drinking, with alcohol intake >7 Standard Drink Units (SDU) per week [9].
In addition, in the US, a survey finds that approximately one in eight pregnant women report alcohol
use [10].
The early diagnosis of alcohol consumption in pregnant women is hampered by the absence of
laboratory markers of continued exposure. During the last decade, efforts have been made to identify
biological markers of exposure during gestation. Clinical interviews and history taking in pregnant
women usually underdiagnose alcohol exposure [11]. The majority of studies on markers of alcohol
consumption during pregnancy have focused on ethanol metabolites derived from non-oxidative
metabolism, such as fatty acid ethyl esters (FAEEs) [12–14], and in the enzymatic conjugation of
ethanol with glucuronide and sulfate [15–18]. Within the last few years, ethyl glucuronide (EtG)
and ethyl sulfate (EtS) have been demonstrated to be markers of fetal alcohol exposure with good
sensitivity and specificity [19]. Meconium, the first fecal matter of the newborn, is a useful substrate
for analysis because it reveals all fetal metabolism from the 12th week of pregnancy onward [20,21].
However, current research suggests that FAEEs may not be adequate markers of alcohol exposure
due to degradation susceptibility arising from environmental conditions [22,23]; in addition, few
studies have simultaneously analyzed both EtG and EtS in meconium samples [24–26]. In addition, the
method of choice for detecting and quantifying direct ethanol metabolites in the meconium is liquid
chromatography-tandem mass spectrometry (LC-MS/MS) [27], a technique that allows the separation
and quantification of different component elements and analysis of their molecular mass [28].
We hypothesized that parturient women barely self-report alcohol consumption and that a
proportion of asymptomatic newborns have been exposed to ethanol. In this sense, we aimed to
analyze prevalence of alcohol consumption in mothers and fetal exposure to ethanol in a series of
parturient women and their newborns following childbirth.
2. Results
2.1. Characteristics of the Study Population
The study population consisted of 51 women and 52 meconium samples (one of the women gave
birth to twins). The median age of the women was 30 years (IQR: 26–34 years). The obstetrics data
(Table S1), pregnancy outcomes (Table S2), and characteristics of newborns (Table S3) are shown in
Appendix A.
According to the questionnaire and clinical charts, overall prevalence of any substance (tobacco,
alcohol, cannabis, cocaine, opiates) use during pregnancy was 41.2% (21/51) and tobacco was the
substance most frequently used (86.7%). Twelve (57%) out of 21 women were substance users but only
3 out of 12 self-reported alcohol consumption during pregnancy. In 43% (9/21), history of substance
use during pregnancy was obtained by reviewing clinical charts.
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2.2. EtG, EtS Determination and Substance Use
Of the 52 meconium samples, 48 were suitable for the analysis of EtG and EtS. EtG was present
in all meconium samples and median concentration of EtG was 67.9 ng/g (IQR: 36.0–110.6 ng/g).
Figure 1a shows the distribution of EtG concentration in meconium. According to the cut-off used
(274 ng/g), two meconium samples tested positive for ethanol despite clinical records, and interview
on alcohol consumption in the respective mothers was negative.
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Figure 1. Distribution of two direct metabolites of ethanol in 48 meconium samples: (a) EtG; and (b) EtS.
With respect to EtS, it was undetectable (<0.01 ng/g) in the majority of meconium samples (79.1%),
and 16.7% tested positive (cut-off: 1.51 ng/g); however, the interview and clinical records for the
respective mothers was negative.
Figure 1b shows the distribution of EtG and EtS concentration in meconium samples.
Figure 2 shows the chromatograms for two positive cases for EtG, and Figure 3 shows the
chromatograms for two positive cases for EtS. As shown in the figures, the qualifier trace was disturbed
by overlapping matrix peaks, and there were no disturbing signals from matrix constituents at EtG
and EtS concentrations. No additional peaks due to endogenous substances that could have interfered
with the detection of metabolites were observed.
The detection of positive levels of EtG or EtS in the meconium samples was not associated with
age of mothers, TPAL (number of term births (T)/number of preterm births (P)/number of abortions
(A)/number of living children (L)), gestational age, compliance of women with antenatal visits, weight
gain during pregnancy, or weight of newborns.
Table 1 summarizes the prevalence of substance use with regard to the information obtained via
structured questionnaires and the detection of direct ethanol metabolites in the meconium samples.
Although not statistically significant, EtG values in the meconium samples were higher in the 21
parturients with substance use: 64 ng/g (IQR: 35–84 ng/g) in those without substance use, 91 ng/g
(IQR: 39.5–120.9 ng/g) in tobacco smokers, and 112 ng/g (IQR: 34.4–112.8 ng/g) in those drinking
alcohol (p = 0.375). Figure 4 shows all the EtG values according to substance use during pregnancy.
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represents the quantification of EtG using the calibration curves. The “multiple reaction monitoring” 
(MRM) program takes into account the following transitions: EtG quantifier 221 > 75 and qualifier 
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Figure 2. Chromatogram in two meconium samples testing positive for EtG. The retention time of
substance ranged from 3 to 3.5 min depending on the column life span. The black line depicts the
quantitative transitions and the blue line depicts the qualitative transitions. The green shade represents
the quantification of EtG using the calibration curves. The “multiple reaction monitoring” (MRM)
program takes into account the following transitions: EtG quantifier 221 > 75 and qualifier 221 > 85,
internal standard (EtG-d5) quantifier 226 > 75 and qualifier 226 > 85. (a) sample EMF_MEC_24 with a
positive concentration of 360 ng/g; (b) sample EMF_MEC_47 with a positive concentration of 420 ng/g.
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Figure 3. Chromatogram in two meconium samples testing positive for EtS. The retention time of
substance ranged from 4.5 to 5.5 min depending on the column life span. The black line depicts the
quantitative transitions and the blue line depicts the qualitative transitions. The green shade represents
the quantification of EtS using the calibration curves. The “multiple reaction monitoring” (MRM)
program takes into account the following transitions: EtS quantifier 125 > 80 and qualifier 125 > 97,
and internal standard (EtS-d5) quantifier 130 > 98 and qualifier 130 > 80. (a) sample EMF_MEC_42
with a positive concentration of 10 ng/g; (b) sample EMF_MEC_12 with a positive concentration of
19.57 ng/g.
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Table 1. Prevalence of substance use during pregnancy according to clinical data of parturient women
and markers of fetal alcohol exposure.
Clinical Information of Parturient Women Markers of Fetal Alcohol Exposure
Substance StructuredQuestionnaire n (%)
Structured
Questionnaire and
Chart Review n (%)
EtG n (%) EtS n (%)
Alcohol 3 (6) 3 (6) 2 (4.2) 8 (16.7)
Tobacco 7 (12) 17 (33.3) NA NA
Cannabis, Cocaine
and/or Opiates 2 (3.9) 3 (6) NA NA
NA: not available.
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3. Discussion
Ethyl glucuronide (EtG) and ethyl sulfate (EtS) have been demonstrated to be good markers of fetal
alcohol exposure [19]. EtG is formed by the ethanol conjugation with glucuronic acid and it is formed
almost entirely in the liver; EtS is formed by the transfer of a sulfuric group from 3’-phosphoadenosine-
phosphosulfate to ethanol in the mitochondria. The results obtained in this study confirm that these
metabolites can be determined in meconium by methods that have been widely validated [28,29].
EtG and EtS are polar, water soluble and stable compounds; LC-MS/MS is the method of choice
for the detection of direct metabolites of ethanol [27,28]. However, a new method for the detection of
EtG–hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC-MS/MS)—has
been recently introduced [30]. In any case, both LC-MS/MS and HILIC-MS/MS, unlike others such
as gas chromatography/flame ionization (GC/FID) and gas chromatography/mass spectrometry
(GC/MS), minimize manual labor by eliminating the solid-phase extraction [30–32].
In this study, the distribution of EtS in meconium samples was similar to that observed in two
Mediterranean cohorts [12,19]; however, in our study median EtG (64 ng/g) was higher than observed
in newborns from Reggio-Emilia from Italy (15.6 ng/g) but it was lower than reported in another study
in Barcelona, Spain (101.5 ng/g) [19]. Interestingly, few studies have simultaneously analyzed both
EtG and EtS in meconium samples [24–26].
Studies of markers of fetal alcohol exposure during pregnancy have shown that EtG and EtS have
similar diagnostic sensitivity and specificity [15–18]. In the present study, we did not evaluate EtG and
EtS as diagnostic tests, but results indicate that, irrespective of the substance used during pregnancy,
EtG levels were higher in meconium samples of newborns whose mothers reported substance use
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compared with pregnant women without substance use. In fact, EtG dose-dependently detects
ethanol consumption [18], and a well-known association exists between tobacco smoke and alcohol
consumption [33–35]. In the present study, higher levels of EtG in newborns of mothers that were
tobacco smokers could indicate occasional alcohol consumption during pregnancy. A study from
Ireland shows that smoking during pregnancy is associated with alcohol consumption and/or other
substance use [36]. More predictors of alcohol drinking during pregnancy include prior history of
consumption and the antecedent of binge drinking [37].
In the present study, only 6% of parturient women report drinking alcohol during pregnancy
and 23% report any substance use including tobacco, cannabis, cocaine, opiates, or alcohol. However,
when the face-to-face interview is complemented by the review of clinical charts, the prevalence of
any substance use during pregnancy is twice as high. Differences in prevalence of substance use
during pregnancy may be related to the minimization or denial of risk behavior by the women after
childbirth [38,39]. Furthermore, some studies have demonstrated the low sensitivity of questionnaires
regarding substance use in pregnant women [11,39]. One recent study on the use of illicit drugs
in Spain showed that only 2% of mothers self reported substance use, whereas the prevalence of
consumption detected by biological markers was 16% [40]. In this study, the results on substance
use from questionnaires did not correlate with those obtained with markers of fetal exposure, as
reported previously [19,40]. A recent meta-analysis indicates that prevalence of prenatal alcohol
exposure as measured by FAEEs in meconium was four times more frequent than prevalence measured
by self-reports [41]. In this study only 6% of the women report alcohol drinking during pregnancy
whereas prevalence of fetal alcohol exposure detected by EtG and EtS in meconium was 4.2% and
16.7%, respectively.
The prevalence of fetal alcohol exposure in this study, regardless of whether it was detected
through the review of the clinical records or through the detection of metabolites in the meconium
samples, was lower than observed in previous studies [42–44]. This funding may be related to the fact
that in our study 29% of the women originated from countries where alcohol drinking is not socially
accepted which could favor a lower prevalence of alcohol consumption in pregnant women. Another
explanation would be related to the fact that the meconium samples in the present study were obtained
from healthy newborns excluding those cases admitted to a neonatal care unit.
The present study has limitations that should be mentioned. First, the assessment of substance use
in a small number of women and newborns limits the generalization of the findings; Second, results
are based on asymptomatic neonates with normal birth weights and Apgar score, thus indicating a
possible selection bias toward healthy newborns. Low birth weight is known to be one of the clinical
manifestations of FASD, and newborns of mothers with substance abuse usually need to be admitted
to intensive neonatal care units; Third, parturients with significant substance use disorders may have
declined to participate in the study. In fact, of the 62 women who were invited to participate, 17.7%
declined. Finally, the cut-off for EtG and EtS used in this study were suggested by previous studies
taking into account the cut-off used in the initial evaluation of FAEEs [29].
4. Materials and Methods
Cross-sectional study conducted in September 2011 and March 2012 in a series of parturient
women who were admitted to the Obstetric Unit at Hospital Universitari Germans Trias i Pujol in
Badalona, Spain, following childbirth and, in the meconium samples from their newborns.
Sixty-two women were informed of the objective of the study; of them, 51 agreed and 11 declined.
The study was approved by the Ethics Committee of the Hospital Universitari Germans Trias i Pujol.
The procedures complied with ethical norms for medical investigations and the principles of good
practice established by the Declaration of Helsinki.
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4.1. Collection of Clinical Data and Biological Samples
A structured questionnaire was administered by a physician to obtain socio-demographic, and
substance use characteristics. This information was complemented by a systematic review of charts,
including the pregnancy characteristics and childbirth records.
We collected the following data from participants: age, anthropometric measurements at the
beginning and the end of pregnancy, history of medical co-morbidity (e.g., hypertension, diabetes
mellitus), the obstetric record via TPAL algorithm, the pharmacological treatment during pregnancy,
biochemical and hematologic parameters from the first trimester of pregnancy, and the degree of
compliance with antenatal visits. With respect to substance use, the administered questionnaire
included the type of substance use including tobacco, alcohol, cannabis, cocaine, and opiate
consumption during pregnancy.
Risk pregnancy was categorized in four levels (no risk, moderate, high, and very high) according
to age of women, substance use, medical co-morbidity, obstetric history and socioeconomic status [45].
To characterize pregnancy outcomes, the following data were collected: week of gestation at birth,
type of birth, birth weight, Apgar test score and immediate birth complications (<48 h).
4.2. Processing and Analysis of Meconium Samples
Meconium samples were refrigerated at 4 ˝C and frozen at ´80 ˝C. Aliquots were analyzed for
EtG and EtG using LC-MS/MS according to a validated method [29].
Sample preparation: 10 to 15 mg of the meconium were diluted with internal standards (EtG-d5
and EtS-d5; Medichem LGC Standards, Wesel, Germany). To homogenize and facilitate separation, the
samples were diluted with 450 µL of water and 500 µL methanol and then sonicated. The samples
were subsequently centrifuged at 16,100 rcf for 30 min and the supernatant was passed by a 3 kDa
filter (Amicon Millipore, Cork, Ireland) and centrifuged at 16,100 rcf for 45 min.
Instrument analysis: Analysis of EtG and EtS was performed by LC-MS/MS using an Agilent 1260
Infinity/6410BA equipment (Agilent Technologies, Palo Alto, CA, USA), which included a Thermo
Hypercarb Column liquid chromatography column (100 mm ˆ 2.1 mm ˆ 5 µm) with a Javelin Guard
Hypercarb (Thermo Fisher Scientific, Waltham, MA, USA). Sixty microliters of the supernatant was
injected at an initial rate of 0.3 mL/min (water:acetonitrile:formic acid, 0.1% v/v) at 45 ˝C. Table 2
shows the chromatograph programming.
Table 2. Chromatograph programming.
Time (min) Flow (mL/min) Phase A: CH3CN 0.1%,Formic Acid %
Phase B: H2O 0.1%,
Formic Acid %
0 0.3 8 92
1 0.3 8 92
4 0.4 0 100
6 0.4 0 100
6.5 0.3 8 92
8 0.3 8 92
Tandem mass spectrometry was performed in negative electrospray ionization (ESI) mode with
a capillary voltage of 4000 V, source temperature of 350 ˝C, curtain gas at 13 L/min, and nebulizer
pressure of 60 psi. The MRM program takes into account the following transitions: EtG quantifier
221 > 75 and qualifier 221 > 85, internal standard (EtG-d5) quantifier 226 > 75 and qualifier 226 > 85,
EtS quantifier 125 > 80 and qualifier 125 > 97, and internal standard (EtS-d5) quantifier 130 > 98 and
qualifier 130 > 80. A summary of MRM is shown in Table 3.
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Table 3. Summaries of multiple reaction monitoring (MRM) for 8 channels.
Component InternalStandard Precursor Fragment
Dwell Time
(msec)
Fragmentor
(Volts)
Collision
Energy (ev)
EtG_d5 IS 226 85 250 100 15
EtG_d5 IS 226 75 250 100 15
EtG - 221 85 250 100 15
EtG - 221 75 250 100 15
EtS_d5 IS 130 98 250 100 15
EtS_d5 IS 130 80 250 100 15
EtS - 125 97 250 100 15
EtS - 125 80 250 100 15
Calibration: a 7-point calibration curve for EtG and EtS was prepared by adding appropriate
volumes of working calibrators and 50 µL of the internal standard (EtG-d5 and EtS-d5) solutions to
0.2 µg/mL of EtG/EtS-free meconium. The calibration curves were linear, with slopes of 0.5–0.7 for
EtG and 0.11–0.2 for EtS, r2 > 0.99. Two selected calibration curves are shown in Appendix B, Figure S1.
The sample concentrations were calculated according to the area under the curve of the sample divided
by the area under the curve of the internal standards, extrapolating from the calibration curve.
4.3. Statistical Analysis
Continuous variables are presented as the median and IQR, and categorical variables are presented
as relative frequencies. The cut-off to determine a positive result (exposure to ethanol) was 274 ng/g
for EtG and 1.51 ng/g for EtS [29].
χ2 tests, Fisher F tests, Student’s t-test, and Mann–Whitney U tests were used to detect significant
differences. Values of p < 0.05 were considered statistically significant. The statistical analysis was
performed using SPSS 15.0 software (SPSS, Chicago, IL, USA).
5. Conclusions
In conclusion, this study provides data of two direct markers of fetal alcohol exposure that confirm
a promising strategy to monitoring substance use in maternal and childcare. The current difficulties in
the early diagnosis of alcohol consumption and substance use during pregnancy makes it necessary to
improve the assessment of fetal exposure using efficient techniques.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/3/
417/s1.
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Abbreviations
EtG ethyl glucuronide
EtS ethyl sulfate
FAEE fatty acid ethyl ester
FAS Fetal Alcohol Syndrome
FASD Fetal Alcohol Spectrum Disorder
IQR interquartile range
LC-MS/MS liquid chromatography—tandem mass spectrometry
NA not available
TPAL number of term births [T]/number of preterm births [P]/number of abortions
[A]/number of living children [L]
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